Last update: January 14th 2016
December 23th 2015

A PRIME example of how EMA is pushing for...

Joint response of Health Action International (HAI), International Society of Drug Bulletins (ISDB), Mario Negri Institute for Pharmacological Research, Medicines in Europe Forum (MiEF), Nordic Cochrane Centre and Wemos to the European Medicines Agency (EMA) public consultation on the...

October 16th 2015

"Adaptive licensing" or "adaptive pathways":...

Joint briefing paper from Health Action International (HAI), The International Society of Drug Bulletins (ISDB), The Medicines in Europe Forum (MiEF), The Mario Negri Institute for Pharmacological Research, The Nordic Cochrane Centre and WEMOS.

"Adaptive pathways"...

March 20th 2015

European Directive on trade secrets: the JURI...

Joint open Letter to the members of the JURI Committee from the Corporate Europe Observatory (CEO), The Medicines in Europe Forum (MiEF) and The International Society of Drug Bulletins (ISDB) calling on the members of the JURI Committee to ensure, through additional and more ambitious...

February 18th 2015

EU Clinical Trials Regulation: EMA steers away...

Joint response to an EMA public consultation

The European Medicines Agency (EMA) must stay true to the Clinical Trials Regulation: non-disclosure has to remain the exception, not become the norm! 

Press release and joint response attached as PDF: 

for members only

NEWSLETTER

2014

November 23th 2014

November


ISDB Publications

Manuals & booklets

October 01th 2008

ISDB Booklet

ISDB Information Booklet
Independence from drug companies is a key element of our policy

booklet october 2008 english (639 KB) - spanish (624 KB)

ISDB - International Society of Drug bullettins

Contact details:
President: president@isdbweb.org
Webmaster: maria.font@ulss20.verona.it

© 2016